Abstract
BackgroundLong-term treatment of anti-TNF agents in patients with immune mediated disease can increase the risk of active tuberculosis infection (ATBI) by reactivation of latent tuberculosis infection (LTBI) or de novo...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have